{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116008","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.042491+00:00","generated_at":"2026-06-08T07:39:55.853915+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Century Therapeutics Q3 net loss $32.7M, appoints Brent Pfeiffenberger CEO","bullets":["Brent Pfeiffenberger appointed CEO effective Dec 4, 2023; Greg Russotti becomes Chief Technology and Manufacturing Officer.","Cash and investments $284.3M as of Sep 30, 2023; cash runway into 2026.","Q3 2023 net loss $32.7M vs $30.7M in Q3 2022; R&D expenses down to $22.8M from $25.9M.","Expanded license with FUJIFILM Cellular Dynamics for iPSC-derived cell therapies in autoimmune/inflammatory diseases.","Initial Phase 1 ELiPSE-1 data for CNTY-101 in B-cell lymphomas to be presented at ASH Dec 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116008","json":"https://secwatch.observer/filing/0001104659-23-116008.json","markdown":"https://secwatch.observer/filing/0001104659-23-116008.md","text":"https://secwatch.observer/filing/0001104659-23-116008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/0001104659-23-116008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/tm2330170d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:39:55.853915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"588a2577643b219204ebf8cba155c1b18e61ee2d","claim":"Century Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $0.1 million, net income $32.7 million. Guidance reaffirmed.","evidence_excerpt":"(BMS) collaboration of $118.5 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option, and license agreement with BMS was $0.1 million for the three months ended September 30, 2023 compared to $2.2 million for the same period in 2022. Revenue recognized under the collaboration agreement fluctuates based on the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/0001104659-23-116008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$0.1 million"},{"label":"Net income","value":"$32.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}